BioSupply Trends - Marketplace News
FFF Enterprises FFF Enterprises | Home FFF Enterprises | Contact Us
December 15, 2011
FFF Enterprises | Patient Safety + Product Efficacy + Fair Pricing
 
In This Issue
  • IVIG Supply Index
  • Albumin Supply Index
  • Open Market Pricing
  • Reimbursement Rates
  • Industry News
  • Subscribe to BST Quarterly
  • Subscribe to IG Living
  • MyFluVaccine Orders
  • Resources
Subscribe to BioSupply Trends eNewsletter
  FFF Enterprises
(800) 843-7477
FFF Enterprises | Free Reference Charts for Hyperimmunes, Immune Globulins, Factor and Injectable Influenza
Hyperimmune
Immune Globulin
Factor
Injectable Influenza
Place Your Flu Vaccine Order on MyFluVaccine.com
Place Your Flu Vaccine Order on MyFluVaccine.com
Subscribe to BioSupply Trends Quarterly magazine
BioSupplyTrends Quarterly magazine, your definitive source for the biopharmaceuticals marketplace
Subscribe to IG Living! magazine
IG Living! magazine, the magazine for the immune globulin community
FFF Enterprises | Helping Healthcare Care - place an order

Flu Vaccine Matches Well with Circulating Viral Strains
The U.S. flu season is mild so far, according to the CDC. That is typical for this early in the season. Influenza activity was low in October and November, according to the latest CDC statistics. They are published in the Dec. 9 issue of the agency's Morbidity and Mortality Weekly Report (MMWR).
Read the full article »

Octapharma Reports octagam® 5% and octagam® 10% Global Sales Totaled 1.7 Million Grams through October with No Thromboembolic Events
"Octapharma's 10-month product analysis confirms our commitment to provide patients with an octagam® 5% and octagam® 10% that offers an enhanced level of safety," said Octapharma Chairman Wolfgang Marguerre. "Industry-wide, immune globulin products can lead to TEEs in approximately 1 individual or less for every 10,000 treatments. But our analysis indicates that octagam® 5% and octagam® 10% outperformed this industry benchmark with no reported TEEs in approximately 60,000 patient treatments."
Read the full article »

 
 
      
 
IVIG Supply Index represents  FFF's aggregate inventory of  all IVIG products for all our  customers who have established  product allocations with us  (not individual or group  allocations).  Blue represents 21 days supply or less, purple is 22 to 29 days, green is 30 days supply or more.  Albumin Supply Index represents FFF's aggregate inventory of Albumin for all our customers who have  established product allocations  with us (not individual or group  allocations). Blue represents 21 days supply or less, purple is 22 to 29 days, green is 30 days supply or more.
 
FFF Enterprises | Open Market Pricing
 
  
 

Steep Discount on Baxter Coseal
FFF has a very limited quantity of short-dated (12/31/11) Baxter Coseal surgical sealant (8 mL) available at deep discount.

Contact FFF's Wow! Customer Care at (800) 843-7477 for details and very favorable pricing.

 
  
 
Current CMS / IVIG Rates
Product Hospital Outpatient Physician's Office
Carimune NF 61.50 62.088
Flebogamma 5% & 10% DIF 70.30* 70.308
Gammagard Liquid 74.86 75.580
Gammagard S/D 61.50 62.088
Gammaked 74.96* 74.968
Gammaplex 74.58* 74.586
Gamunex-C 74.26 74.968
Octagam 112.675† 113.748‡
Privigen 69.50 70.160

*ASP + 6% (Medicare pass-through drug)
WAC + 5% (based on Wholesale Acquisition Cost until ASP is re-established)
WAC + 6% (based on Wholesale Acquisition Cost until ASP is re-established)
Rates per gram are effective October 1, 2011 through December 31, 2011.

 
  
 

Industry News

From NYTimes.com
Gene Therapy Used to Treat Hemophilia B
more »

From Science Daily
New Vaccine Attacks Breast Cancer in Mice
more »

From CDC
CDC Issues Recommendations on Use of New Treatment Option for Latent TB Infection
more »

From Sanofi
Sanofi Reports Positive Results for Once-daily Lyxumia® (lixisenatide) in Combination with Lantus® (insulin glargine) in Type 2 Diabetes
more »

 
 
 
   
   
 
FFF Enterprises | Patient Safety + Product Efficacy + Fair Pricing
Home | About Us | Contact   ©2011 FFF Enterprises, Inc.